BRD4 and cancer: Because an increasing number of studies have shown that BRD4/BET inhibitors and kinase inhibitors might act synergistically in a range of cancer types (Sun et al., 2015), the predicted off-target interactions with kinases might provide clues and starting points for further study of related dual functional inhibitors (Timme et al., 2020).